CD20 Marker and Relevance to Lymphoma

CD20 is a CD marker—a molecule on the cell surface that can be used to identify and type a particular cell in the body. CD20 is found on the surface of B cells, but let's back up and make this easier to understand.

A patient receives treatment for Hodgkin's lymphoma
Bryn Lennon / GettyImages

What Are CD Markers?

CD markers are molecules that are found on the surface of cells in our bodies. You may hear them called antigens—and an antigen is basically anything on the surface of a cell that can be recognized by our immune system. For example, our white blood cells may recognize antigens on the surface of bacterial invaders and the white cells have the ability to respond to what is correctly perceived as a threat.

Every cell in our bodies has a CD marker, and altogether there are more than 250 of these antigens. The term CD stands for cluster of differentiation—and again, is one way in which different kinds of cells can be told apart. Being able to identify these CD markers can be especially important when you cannot otherwise recognize the type of cell.

CD Markers, B Cells, and T Cells

Lymphomas are cancers of the type of white blood cell known as lymphocytes. There are two main types of lymphocytes—B lymphocytes or B cells, and T lymphocytes or T cells. Both types of lymphocytes help to protect our bodies from infections.

B cells and T cells have different functions, and cancers of each of the B cells act differently from cancers of the B cells. Despite all of these differences, it can be difficult to tell the difference between the two under a microscope. Kind of like two identical twins who behave very differently and respond to people differently but look alike on the outside.

What Is CD20?

CD20 is an antigen that is found on the surface of B cells but not T cells. An example of how CD-20 can be used to tell cells apart is given here:

There are two very different cancers that look like identical twins under the microscope, but have very different disease courses and respond differently to treatments: Diffuse large B cell lymphoma (DLBCL) is cancer involving B cells. Under the microscope, the cells look just like the cancerous T cells found in anaplastic large cell lymphoma (ALCL). Both of these cancers have large, "cancery" looking cells and can be otherwise indistinguishable. CD20 can be used to tell the difference between these two cancers in that test results for CD20 would usually be positive in the case of DLBCL but negative for ALCL.

How Is It Tested?

A special technique called immunohistochemistry (IHC) is used to identify CD20 and determine whether an abnormal cancerous white blood cell (lymphocyte in particular) is a B-cell or T-cell.


Treatment and prognosis for B-cell and T-cell lymphomas are often different.

A newer category of medications called monoclonal antibodies work very well for some lymphomas. Just as our bodies make antibodies to fight off bacteria and viruses, monoclonal antibodies are man-made antibodies designed to fight off cancer cells. And just as our bodies make antibodies that recognize antigens on bacteria an viruses, these monoclonal antibodies recognize antigens on the surface of cancer cells; in this case, CD20.

Using a monoclonal antibody that binds to CD20 will therefore only work against a cancer with CD20 antigens on the surface, such as DLBCL in the analogy above.

Monoclonal Antibody Treatment and CD20

There are several monoclonal antibodies that are now being used. The monoclonal antibodies that treat B cell lymphomas and leukemias with the CD20 antigen on the surface of the cells include:

  • Rituxan (rituximab)
  • Zevalin (ibritumomab tiuxetan)
  • Bexxar (tositumomab)
  • Gazyva (obinutuzumab)
  • Arzerra (ofatumumab)

Though they all bind CD20, there are differences among these antibodies. Some are referred to as chimeric such as rituximab, which means the bio-engineers used a 'mix of construction materials' to craft the antibody, some human, some mouse; some are humanized (obinutuzumab) and some are fully human (ofatumumab), meaning all parts come from human gene => protein sources. Then, another differentiating factor is that some are linked to a radioactive elements (ibritumomab tiuxetan and tositumomab).

Coping With Lymphoma

As you've reached this page, you are taking a great step forward in being an active participant in your care. Studies have found that learning as much about your disease as possible, and playing an active role in your care, helps not only cope with the anxiety of cancer but may help with outcomes as well. Reach out to family and friends. Check into the wonderful online community of people with leukemia and lymphoma—people you can access 24/7 for support and with questions. And make sure you are your own advocate in your cancer care. Medicine is changing and oncologists not only tolerate but expect to work side by side with you to tailor a treatment program that is best for you as a person.

7 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. How does your body normally resist infections?. American Cancer Society.

  2. Boyd SD, Natkunam Y, Allen JR, Warnke RA. Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results. Appl Immunohistochem Mol Morphol. 2013;21(2):116-31.  doi:10.1097/PAI.0b013e31825d550a

  3. Monoclonal Antibodies and Their Side Effects. American Cancer Society.

  4. American Cancer Society. Immunotherapy for Non-Hodgkin Lymphoma.

  5. Highlights Of Prescribing Information: Bexxar. US Food & Drug Administration.

  6. Highlights Of Prescribing Information: Arzerra. US Food & Drug Administration.

  7. Levit L, Balogh E, Nass S, et al., editors. Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis. National Academies Press.

Additional Reading
  • National Cancer Institute. Adult Non-Hodgkin Lymphoma Treatment – Health Professional Version (PDQ).

By Indranil Mallick, MD
 Indranil Mallick, MD, DNB, is a radiation oncologist with a special interest in lymphoma.